F2 and thrombophilia: Considering that the nAPCsr is able to detect with 97% sensibility patients with FVL or with prothrombin mutation, the two more prevalent thrombophilia in the European population (53), we can estimate that near 59% of the population suffering from COC-associated VTE will be correctly oriented to less thrombotic contraceptive solutions.